Keyphrases
Lung Cancer
100%
Pathological Response
100%
Neoadjuvant Therapy
100%
Viable Tumor
100%
Event-free Survival
70%
Primary Tumor
50%
Chemotherapy
30%
Lymph Node
30%
Hazard Ratio
20%
Resectable Lung Cancer
20%
Pathological Complete Response
20%
Radiological Response
20%
Nivolumab
20%
Tumor-associated
10%
Tumor Regression
10%
Circulating Tumor DNA (ctDNA)
10%
Tumor Subtype
10%
Survival Rate
10%
Programmed Death-ligand 1 (PD-L1)
10%
Lymph Node Involvement
10%
Area under the Curve
10%
Scoring System
10%
Advanced Disease
10%
Neoadjuvant
10%
Tumor Necrosis
10%
Response Assessment
10%
Lung-other
10%
Pan-cancer
10%
DNA Clearance
10%
CheckMate
10%
Neoadjuvant Immunotherapy
10%
Major Pathologic Response
10%
Medicine and Dentistry
Neoplasm
100%
Lung Cancer
100%
Neoadjuvant Therapy
100%
Event Free Survival
63%
Primary Tumor
45%
Lymph Node
36%
Hazard Ratio
18%
Nivolumab
18%
Disease
9%
Immunotherapy
9%
Survival Rate
9%
Tumor Regression
9%
Tumor Necrosis
9%
Scoring System
9%
Sodium Fluoride
9%
Circulating Tumor DNA
9%
Programmed Death 1 Receptor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Lung Cancer
100%
Event Free Survival
63%
Primary Tumor
45%
Chemotherapy
27%
Nivolumab
18%
Disease
9%
Immunotherapy
9%
Survival Rate
9%
Tumor Regression
9%
Tumor Necrosis
9%
Sodium Fluoride
9%
Circulating Tumor DNA
9%
Programmed Death 1 Receptor
9%